Skip to content

13F-HR filed by Saturn V Capital Management LP

Saturn V Capital Management LP filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 24 holding rows worth $255,366,661.

Accession
0001964437-25-000003
Filed
2025-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2024

A holdings report, 24 entries on the cover page, a total value of $255,366,661 stated on the cover page (in dollars after the unit check, H1), rows summing to $255,366,661 with VALUE read as dollars as filed, 13F file number 028-22863. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
DISC MEDICINE INC COM254604101Stock509,406$32,296,340dollars as filed
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR198,977$27,393,164dollars as filed
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock346,111$18,741,911dollars as filed
CG ONCOLOGY INC156944100COMMON STOCK593,262$17,014,754dollars as filed
VAXCYTE INC COM92243G108Stock204,285$16,722,770dollars as filed
CYTOKINETICS INC23282W605COM NEW348,364$16,387,043dollars as filed
CARGO THERAPEUTICS INC COM14179K101Stock1,007,677$14,530,702dollars as filed
CELCUITY INC15102K100COM1,063,783$13,924,919dollars as filed
SYNDAX PHARMACEUTICALS INC87164F105COM988,528$13,068,340dollars as filed
XENON PHARMACEUTICALS INC COM98420N105Stock322,470$12,640,824dollars as filed
ARGENX SE SPONSORED ADR04016X101ADR19,754$12,148,710dollars as filed
COGENT BIOSCIENCES INC19240Q201COM1,498,425$11,687,715dollars as filed
MERUS N VN5749R100COM234,637$9,866,486dollars as filed
CONTINEUM THERAPEUTICS INC CL A21217B100Stock573,022$8,394,772dollars as filed
ABIVAX SA-00370M103SPONSORED ADS653,071$4,780,480dollars as filed
KALVISTA PHARMACEUTICALS INC483497103COM556,489$4,713,462dollars as filed
INOZYME PHARMA INC45790W108COM1,374,582$3,807,592dollars as filed
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK814,533$3,608,381dollars as filed
AMYLYX PHARMACEUTICALS INC03237H101COM889,073$3,360,696dollars as filed
CRINETICS PHARMACEUTICALS INC COM22663K107Stock59,125$3,023,061dollars as filed
SILENCE THERAPEUTICS PLC82686Q101ADS395,024$2,717,765dollars as filed
NEWAMSTERDAM PHARMA CO NVN62509109COMMON STOCK100,000$2,570,000dollars as filed
OCULAR THERAPEUTIX INC67576A100COM191,456$1,635,034dollars as filed
MBX BIOSCIENCES INC COM55287L101Stock18,000$331,740dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001964437-25-000003this filing2025-02-14acceptance time not in the bulk data set